United States Biomarkers Market to Grow at 11.9% CAGR, Driven by Precision Medicine Adoption and Companion Diagnostic Development | DataM Intelligence

The global biomarkers market reached US$ 60.76 billion in 2024 and is expected to reach US$ 148.88 billion by 2032, growing at a CAGR of 11.9% during the forecast period 2025-2032, according to DataM Intelligence.

United States: Recent Industry Developments

✅ In October 2025, Roche Diagnostics launched a comprehensive multi-cancer early detection blood test analyzing 50 different protein biomarkers.
✅ In September 2025, The FDA approved a novel digital biomarker platform using smartphone sensors for real-time Parkinson's disease monitoring.
✅ In August 2025, Abbott Laboratories introduced a point-of-care biomarker testing system delivering results in 15 minutes for emergency cardiac care.

Europe: Recent Industry Developments

✅ In October 2025, Thermo Fisher Scientific established a new biomarker discovery center in Cambridge, UK, focusing on neurodegenerative diseases.
✅ In September 2025, The European Medicines Agency approved new guidelines for biomarker validation in clinical trial endpoints.
✅ In August 2025, Bio-Rad Laboratories developed a multiplex biomarker panel for autoimmune disease diagnosis and monitoring.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/biomarkers-market?jd

Asia-Pacific: Recent Industry Developments

✅ In October 2025, Sysmex Corporation launched an AI-powered biomarker analysis platform for early cancer detection in Asian populations.
✅ In September 2025, China's National Medical Products Administration fast-tracked approval for 10 novel biomarker-based diagnostic tests.
✅ In August 2025, Wuxi Diagnostics introduced a cost-effective biomarker screening kit for cardiovascular risk assessment in primary care settings.

Market Trends & Drivers

The Biomarkers Market is experiencing rapid growth driven by the shift toward personalized medicine, increasing prevalence of chronic diseases, and advancements in genomic and proteomic technologies. Key trends include the development of liquid biopsy biomarkers, integration of artificial intelligence in biomarker discovery, and expansion of point-of-care biomarker testing. The growing focus on early disease detection, rising pharmaceutical R&D investments, and regulatory support for companion diagnostics are significantly accelerating market expansion.

Buy now and enjoy a 30% year-end discount - limited-time offer! https://www.datamintelligence.com/buy-now-page?report=biomarkers-market?jd
(Purchase 2 or more Reports and get 50% Discount)

Competitive Landscape

The market features intense competition among diagnostic companies, pharmaceutical developers, and technology innovators.

1. Roche Diagnostics leads in companion diagnostics and comprehensive biomarker testing solutions.
2. Abbott Laboratories dominates in point-of-care biomarker testing and cardiovascular diagnostic platforms.
3. Thermo Fisher Scientific provides extensive biomarker research tools and clinical diagnostic assays.
4. Bio-Rad Laboratories, Inc. specializes in biomarker detection systems and quality control materials.
5. Siemens Healthineers offers automated biomarker testing systems for clinical laboratories.
6. Danaher Corporation (through Beckman Coulter) provides integrated biomarker analysis platforms.
7. Merck KGaA supplies critical reagents and tools for biomarker research and development.
8. Qiagen N.V. specializes in sample preparation technologies for biomarker analysis.
9. Myriad Genetics, Inc. focuses on genetic biomarkers for hereditary cancer and risk assessment.
10. Sysmex Corporation develops hematological and molecular biomarkers for disease monitoring.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biomarkers-market?jd

Segmentation

By Product Type (Diagnostic Biomarkers, Monitoring Biomarkers, Predictive Biomarkers, Susceptibility/Risk Biomarkers, Prognostic Biomarkers, Pharmacodynamic/Response Biomarkers, Safety Biomarkers, Others)
By Application (Drug Discovery and Development, Disease Diagnostics, Disease Risk Assessment, Personalized Medicine, Others)
By End-User (Pharmaceutical Companies, Biotechnology Companies, Research Centers and Institutes, Others)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (Germany, U.K., France, Italy, Spain, Netherlands, Rest of Europe)
⇥ Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
⇥ South America (Brazil, Argentina, Chile, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a market research and consulting firm that bridges the gap between data and decisive action. We specialize in translating top market trends and in-depth analysis into swift, smart solutions for your business.
With a repository of 6,300+ reports across 40+ industries, we provide the robust intelligence that over 200 companies in 50+ countries rely on to power their growth.

This release was published on openPR.